1
|
Czirbesz K, Pánczél G, Baranyai F, Kispál M, Tóth E, Bőcs K, Balatoni T, Fröhlich G, Liszkay G. [BRAF-MEK inhibitor therapy in melanoma]. Magy Onkol 2022; 66:110-117. [PMID: 35724387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 05/28/2022] [Indexed: 06/15/2023]
Abstract
We investigated the efficacy and safety of vemurafenib+cobimetinib (V+C) and dabrafenib+trametinib (D+T) based on real-life data. From 2015 and 2018 we have selected 118 BRAF-mutated metastatic melanoma patients, treated with V+C and D+T in our institute. We retrospectively analyzed the overall response rate (ORR), the progression-free survival (PFS), the overall survival (OS) and the adverse events of the therapies. The median follow-up time was 18 months (3-43) with V+C and 12 months (3-43) with D+T. The median PFS was 8 months in the V+C and 8.5 months in the D+T group. Median OS was 18 months in V+C group and 12 months with D+T. The ORR was revealed to be 82% in D+T group and 76% in V+C group. Each combination displayed a slightly different safety profile. In our retrospective analysis both BRAF-MEK inhibitor combination therapies showed favorable efficacy with a slightly different spectrum of toxicity profile.
Collapse
Affiliation(s)
- Kata Czirbesz
- Onkodermatológai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Gitta Pánczél
- Onkodermatológai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Fanni Baranyai
- Onkodermatológai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Mihály Kispál
- Onkodermatológai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Erika Tóth
- Nemzeti Tumorbiológiai Laboratórium, Országos Onkológiai Intézet, Budapest, Hungary
| | - Katalin Bőcs
- Nemzeti Tumorbiológiai Laboratórium, Országos Onkológiai Intézet, Budapest, Hungary
| | - Tímea Balatoni
- Onkodermatológai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Georgina Fröhlich
- Nemzeti Tumorbiológiai Laboratórium, Országos Onkológiai Intézet, Budapest, Hungary
| | - Gabriella Liszkay
- Onkodermatológai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| |
Collapse
|
2
|
Balatoni T, Ladányi A, Fröhlich G, Czirbesz K, Kovács P, Pánczél G, Bence E, Plótár V, Liszkay G. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Pathol Oncol Res 2020; 26:317-325. [PMID: 30225783 DOI: 10.1007/s12253-018-0466-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Accepted: 08/29/2018] [Indexed: 12/11/2022]
Abstract
Ipilimumab was the first immunotherapy approved for metastatic melanoma in decades and is currently registered as a second-line treatment. However, new immunotherapies, in combination with ipilimumab, offer even better clinical outcomes for patients compared with single-agent treatments, at the expense of improved toxicity. The aim of this study was to evaluate the feasibility of ipilimumab outside the clinical trials and to identify survival predictors for treatment benefit. Data were collected on 47 advanced melanoma patients treated with ipilimumab between 2010 and 2015 at a single center. Association of clinical characteristics (including primary tumor characteristics), serum lactate dehydrogenase (LDH), erythrocyte sedimentation rate, absolute eosinophil, lymphocyte, and neutrophil count, neutrophil/lymphocyte and eosinophil/lymphocyte ratio with toxicity and clinical outcome were assessed using univariate and multivariate analysis. Median progression-free survival at a median follow-up of 10 months was 2.7 months and median overall survival was 9.8 months. Objective response was observed in 17% of patients and the disease control rate at week 24 was 40%. The 1- and 2-year survival rates documented were 40 and 28%, respectively. Significant association between high LDH level (>1.5× upper limit of normal) and decreased overall survival was demonstrated in uni- and multivariate analysis (hazard ratio [HR]: 3.554, 95% CI: 1.225-10.306, p = 0.019). Neither biomarkers nor clinical outcome were associated with toxicity. Using baseline serum LDH to identify patients most likely to benefit from ipilimumab therapy could serve as a simple and inexpensive biomarker of clinical outcome.
Collapse
Affiliation(s)
- Tímea Balatoni
- Department of Oncodermatology, National Institute of Oncology, 7-9. Ráth Gy. u., Budapest, H-1122, Hungary.
| | - Andrea Ladányi
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary
| | - Georgina Fröhlich
- Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary
| | - Kata Czirbesz
- Department of Oncodermatology, National Institute of Oncology, 7-9. Ráth Gy. u., Budapest, H-1122, Hungary
| | - Péter Kovács
- Department of Oncodermatology, National Institute of Oncology, 7-9. Ráth Gy. u., Budapest, H-1122, Hungary
| | - Gitta Pánczél
- Department of Oncodermatology, National Institute of Oncology, 7-9. Ráth Gy. u., Budapest, H-1122, Hungary
| | - Eszter Bence
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary
| | - Vanda Plótár
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary
| | - Gabriella Liszkay
- Department of Oncodermatology, National Institute of Oncology, 7-9. Ráth Gy. u., Budapest, H-1122, Hungary
| |
Collapse
|
3
|
Szabó B, Szűcs M, Horváth A, Székely E, Pánczél G, Liszkay G, Holló P, Wikonkál N, Nyirády P. [Mucosal melanoma primary and metastatic cases with urogenital localization in our department]. Orv Hetil 2019; 160:378-385. [PMID: 30829059 DOI: 10.1556/650.2019.31303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Both primary and metastatic cases of mucosal melanoma in urogenital localization are rare tumors. Only 4-5% of all primary melanomas do not arise from the skin. Extracutaneous melanomas have a complex clinical presentation, but these aggressive tumors have a poor prognosis. MATERIALS AND METHOD In our department, we found 7 patients with malignant melanoma of the genitourinary tract in the past few years. The 7 cases were: primary amelanotic melanoma of the female urethra, a primary melanoma of the bladder, two primary melanomas of the penis, a metastatic melanoma of the urethra and another to the testis and a metastatic melanoma of the bladder with melanuria. We retrospectively analyzed the available data to describe the presentation, management, and clinical outcome of the patients. RESULTS In the three inoperative cases, palliative, urologic surgical procedures and systemic antitumor therapy were performed. Two of the four primary urogenital tumors were localized to the penis. In one case, local recurrence developed after surgical treatment, but with a radical, repeated surgery, the patient has been asymptomatic for a year and a half. In the other, neglected case, the penis melanoma spread through the urethra and the inguinal lymph nodes two years after radical surgery and inguinal block dissection. In the female primary urethral melanoma case, the first histological study reported a primary mesenchymal tumor, and the recurrent tumor that occurred one and a half years later showed melanoma diagnosis. Radical surgery performed because of urethral involvement resulted in a 5-year asymptomatic state, followed by local recurrence and distant metastasis. In the fourth case of a primary bladder melanoma, the rapid progression of the disease and the BRAF positivity of the tumor suggested that not the firstly diagnosed bladder melanoma was the primary tumor. CONCLUSION The occurrence of urinary tract melanoma is very rare and its discovery happens often in a disseminated state, so the expected prognosis of the cases is also poor. The most important factors for increasing therapeutic efficacy are early diagnosis and radical surgical intervention. Tumors appearing in different localizations require different urological surgical approaches. The literature recommendations for treatment are not uniform. Their prognosis is worse compared to the cutaneous melanoma, which may be due to clinical and pathological diagnostic difficulties. The latest targeted and immunotherapeutic agents can significantly improve the survival of metastatic patients. Orv Hetil. 2019; 160(10): 378-385.
Collapse
Affiliation(s)
- Balázs Szabó
- Urológiai Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Üllői út 78/B, 1082
| | - Miklós Szűcs
- Urológiai Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Üllői út 78/B, 1082
| | - András Horváth
- Urológiai Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Üllői út 78/B, 1082
| | - Eszter Székely
- II. Patológiai Intézet, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest
| | | | | | - Péter Holló
- Bőr-, Nemikórtani és Bőronkológiai Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest
| | - Norbert Wikonkál
- Bőr-, Nemikórtani és Bőronkológiai Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest
| | - Péter Nyirády
- Urológiai Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Üllői út 78/B, 1082
| |
Collapse
|
4
|
Imrédi E, Plótár V, Szavcsur P, Pánczél G, Melegh K, Schlachter K, Liszkay G. [Treatment of metastatic progression following the synchronous occurrence of cutaneous and ocular primary melanomas]. Orv Hetil 2018; 159:642-647. [PMID: 29658281 DOI: 10.1556/650.2018.31018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The incidence rates of cutaneous melanoma in non-Hispanic whites show an increasing tendency with age. While uveal melanoma in general is a rare disease, representing only 4% of all melanomas with an incidence rate of 0.6 per 100 000, it is still the most frequent malignancy of the eye. Synchronous occurrence of ocular and cutaneous melanoma is an exceptional rarity, due to the distinct genetic background of the diseases. We report the case of a 80-year-old man who underwent total excision of a cutaneous melanoma in 2008. In 2013, he was diagnosed with uveal melanoma as part of a routine work-up for reduced vision. The uveal melanoma was treated by brachytherapy. In 2015, liver metastases were suspected by routine ultrasonography. Core biopsy was carried out, and the histology confirmed melanoma metastases. The molecular analysis of the cutaneous lesion showed gain of function mutation of the BRAF V600 K gene, while we found a wild-type BRAF gene in the metastatic lesion. Based on the recommendation of the oncoteam, hepatic intra-arterial Epirubicin-Platidiam therapy was introduced. He received 11 doses of intra-arterial chemotherapy (IAC), in 21 cycles. IAC was well tolerated without any catheter-related complications or toxicities. Partial regression of the hepatic metastases were documented in February 2016. After completing the eleventh cycle of intrahepatic chemotherapy, the disease remained in complete remission for over a year. The parallel occurrence of cutaneous and ocular melanoma is rare, however, the metastatic progression in such cases make the selection of optimal medical therapy challenging. The distinct genetic background of two melanoma types may help the identification of the source of the metastatic lesions, in order to guide the treatment decisions. Orv Hetil. 2018; 159(16): 642-647.
Collapse
Affiliation(s)
- Eleonóra Imrédi
- Bőrgyógyászati Osztály, Országos Onkológiai Intézet Budapest, Ráth György utca 7-9., 1122
| | - Vanda Plótár
- Molekuláris Patológiai Osztály, Országos Onkológiai Intézet Budapest
| | - Péter Szavcsur
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet Budapest
| | - Gitta Pánczél
- Bőrgyógyászati Osztály, Országos Onkológiai Intézet Budapest, Ráth György utca 7-9., 1122
| | - Krisztina Melegh
- Bőrgyógyászati Osztály, Országos Onkológiai Intézet Budapest, Ráth György utca 7-9., 1122
| | | | - Gabriella Liszkay
- Bőrgyógyászati Osztály, Országos Onkológiai Intézet Budapest, Ráth György utca 7-9., 1122
| |
Collapse
|
5
|
Kovács P, Pánczél G, Melegh K, Balatoni T, Pörneczy E, Lõrincz L, Czirbesz K, Gorka E, Liszkay G. [Psychological aspects of immunotherapies in the treatment of malignant melanoma]. Magy Onkol 2016; 60:22-27. [PMID: 26934347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Accepted: 12/12/2015] [Indexed: 06/05/2023]
Abstract
Psychological problems may arise in connection with oncomedical treatments in three ways: 1. acute and/or 2. chronic ways, as well as 3. co-morbid psychiatric diseases that already exist must also be taken into account. Immunotherapies have the most common and also clinically relevant psychological side effects. Fatigue, anhedonia, social isolation, psychomotor slowness is reported during treatment. Anti-CTLA-4 antibody (ipilimumab) immunotherapy can present one of the most modern opportunities for adequate treatment for patients having distant metastasis or unresectable tumour. In relation to immunotherapies, acute psychological side effects (acute stress) emerging during treatments develop in a way that can mostly be linked to environmental factors, e.g. notification of diagnosis, hospitalisation, progression, deterioration in quality of life, imminent dates of control. Crisis is a temporary and threatening condition that endangers psychological balance. In such conditions, enhanced psychological vulnerability must be taken into account and doctors play a key role in the rapid recognition of the condition. Chronic psychological problems, which may arise from the depressogenic effect of the applied treatment or originated from a pre-melanoma psychiatric condition, may exceed the diagnostic and psychotherapeutic competences of a clinical psychologist. Even in case of a well-defined depressogenic biological mechanism such as the activation of the pro-inflammatory cytokine pathway, positive environmental effects can reduce symptoms and thus increase compliance. Side effects can be treated successfully using psychotherapeutic methods and/or psychiatric medicines. The application of routinely used complex psychosocial screening packages can provide the easiest method to identify worsening psychological condition during immunotherapy and give rapid feedback to the oncologist and the patient. Team work is of particular importance in a situation like this as it requires complex, interdisciplinary and high-level professional collaboration. Multidisciplinarity is the basic framework for modern tumour therapy where, under the guidance of oncologists, the work of specialist nurses, social workers, physiotherapists, dieticians and last but not least psychiatrists/psychologists are indispensable and play a significant role.
Collapse
Affiliation(s)
- Péter Kovács
- Mentális Egészségtudományok Doktori Iskola, Semmelweis Egyetem, Budapest, Hungary
| | - Gitta Pánczél
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Krisztina Melegh
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Tímea Balatoni
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Edit Pörneczy
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Lenke Lõrincz
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Kata Czirbesz
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Eszter Gorka
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Gabriella Liszkay
- Bõrgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| |
Collapse
|
6
|
Kovács P, Pánczél G, Balatoni T, Liszkay G, Gonda X, Bagdy G, Juhasz G. Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients. J Psychosom Res 2015; 78:579-84. [PMID: 25801845 DOI: 10.1016/j.jpsychores.2015.03.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Revised: 02/23/2015] [Accepted: 03/06/2015] [Indexed: 01/06/2023]
Abstract
OBJECTIVE The most frequent serious psychological side effect of immune therapies is depression. In the present study, we tested whether social support, as a positive environmental effect, is able to moderate depression or anxiety symptoms in melanoma patients during adjuvant low-dose interferon treatment. METHODS Hundred and twenty-seven melanoma patients with negative psychiatric history were included in our longitudinal study and followed up for one year. Depression and anxiety symptoms were measured six times during treatment: at baseline, at 1st, 3rd, 6th, 9th and 12th month of the therapy. In addition, social support was investigated with the Social Dimension Scale. RESULTS Depressive symptoms significantly increased during the 12-month follow-up period (p<0.001). However, social support significantly moderated the depressogenic effect of low-dose interferon treatment (p<0.001). Patients with better social support showed attenuated increase of depression. Anxiety showed no significant changes during the low-dose interferon treatment (p=0.230). Social support had no moderating effect on anxiety symptoms (p=0.745) during the follow up. DISCUSSION Our data provide evidence that social support and interferon alpha treatment significantly interact in the development of depression. In addition, our study emphasises that enhancement of social support can reduce depressogenic side effects and increase compliance during adjuvant interferon treatment, and thus, psychological screening and psychooncological counselling should be incorporated in the treatment protocol.
Collapse
Affiliation(s)
- Péter Kovács
- National Institute of Oncology, Budapest, Hungary; Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary.
| | | | | | | | - Xenia Gonda
- Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary; MTA-SE Neuropsychopharmacology and Neurochemistry Research Group, Budapest, Hungary; Department of Clinical and Theoretical Mental Health, Semmelweis University, Budapest, Hungary.
| | - Gyorgy Bagdy
- Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary; MTA-SE Neuropsychopharmacology and Neurochemistry Research Group, Budapest, Hungary.
| | - Gabriella Juhasz
- Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary; MTA-SE Neuropsychopharmacology and Neurochemistry Research Group, Budapest, Hungary; Neuroscience and Psychiatry Unit, University of Manchester, UK; MTA-SE-NAP-B Genetic Brain Imaging Migraine Research Group, Hungarian Brain Research Program, Budapest, Hungary.
| |
Collapse
|
7
|
Kovács P, Pánczél G, Borbola K, Juhász G, Liszkay G. Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy—A Follow-Up Study of First Experiences. Pathol Oncol Res 2014; 20:939-44. [DOI: 10.1007/s12253-014-9777-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Accepted: 04/09/2014] [Indexed: 01/06/2023]
|
8
|
Pánczél G, Liszkay G, Borbola K, Balatoni T, Hunyadi J. [The importance of fine needle aspiration cytology in the management of recurrent and metastatic melanoma]. Orv Hetil 2012; 153:1419-23. [PMID: 22951409 DOI: 10.1556/oh.2012.29434] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
UNLABELLED Fine needle aspiration cytology is a widely accepted, reliable diagnostic modality for the early detection of metastases. OBJECTIVE Quality assurance analysis of fine needle aspiration cytology in melanoma patients. METHOD A total of 194 biopsies performed in 142 melanoma patients were analyzed retrospectively. RESULTS 138 (71.13%) cutaneous or subcutaneous nodules and 56 (28.87%) palpable lymph nodes were studied. 87 (44.85%) true positive, 92 (47.42%) true negative, 3 (1.55%) false positive and 12 (6.19%) false negative cytology results were found. High sensitivity (87.89%), specificity (96.84%) and diagnostic accuracy (93.72%) were confirmed. DISCUSSION The quality assurance of fine needle aspiration biopsy in these patients with recurrent and metastatic melanoma meets the international requirements.
Collapse
Affiliation(s)
- Gitta Pánczél
- Országos Onkológiai Intézet Budapest Ráth György u. 7-9. 1122.
| | | | | | | | | |
Collapse
|
9
|
Abstract
OBJECTIVES When the vascular disorder of the cochleovestibular system is mentioned, the diagnosis is based on exclusion of other diseases. Since arteries of the cochleovestibular system cannot be directly visualized, physicians must deduce from the vascular risk factors and the vascular lesion of other territories to the vascular cochleovestibular disease. MATERIALS AND METHODS Authors analyzed the data of 19 patients with vertigo. Detailed blood tests, complete neurootological and audiological examination including ABR, carotid and vertebral artery Doppler sonography, MRI and MRA was performed. RESULTS Cochleovestibular examination and ABR showed abnormalities in 73.7%, either carotid and vertebral artery Doppler or MRI showed abnormalities in 57.9%. MRA was abnormal in 47.4%. In most of the patients multiple risk factors of cerebrovascular disorder could be found. CONCLUSIONS The cochleovestibular system disorders can be considered to be of vascular origin if the examinations exclude other diseases, if the patients have vascular risk factors and if other territories of brain accessible for imaging methods show vascular disorders.
Collapse
Affiliation(s)
- A Szirmai
- Semmelweis University, Budapest, Department of Otolaryngology and Head and Neck Surgery, H-1083, Szigony u 36, Budapest, Hungary.
| | | | | | | | | | | |
Collapse
|
10
|
Naményi M, Puha K, Pánczél G, Mikó P, Fäller K, Dér K. [Zafirlukast therapy of patients with mild-to-moderate bronchial asthma]. Orv Hetil 1999; 140:1353-6. [PMID: 10439636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The recently compiled clinical experiences support the previous theory, that the cysteinil-leukotriens have an important role in the pathomechanism of bronchial asthma. Zafirlukast is a selective antagonist of the receptor 1 of cysteinil-leukotriens, and its use reduces the severity of asthma symptoms. The effect of 20 mg zafirlukast b.i.d was studied in 31 patients with mild-moderate asthma bronchiale. During the 6 week treatment period, even several hours after the first zafirlukast dose the pulmonary function improved significantly. This effect sustained during the whole treatment period, the patients' symptoms lessened and there was a significant reduction in the frequency of beta-2 agonist's use. No adverse events causally related to zafirlukast's use were detected. Zafirlukast is an efficient therapy of mild to moderate asthma bronchiale.
Collapse
Affiliation(s)
- M Naményi
- Veszprém Megyei Csolnoky Ferenc Kórház Rendelöintézet, Veszprém, Tüdögondozó
| | | | | | | | | | | |
Collapse
|
11
|
Afra J, Ertsey C, Jelencsik H, Dabasi G, Pánczél G. SPECT and TCD studies in cluster headache patients. Funct Neurol 1995; 10:259-64. [PMID: 8837989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We investigated regional cerebral blood flow (rCBF) with Tc99m-HMPAO single photon emission computed tomography (SPECT) and blood flow velocity in the middle cerebral artery (MCA) with transcranial Doppler (TCD) ultrasound. Nineteen cluster headache patients participated in the study, 9 of them underwent both examinations, whereas in 6 patients only SPECT and in 4 patients only TCD was performed. Patients were examined during spontaneous and/or provoked attacks and when symptom-free in a cluster period. Six patients showed moderate frontal hyperperfusion, 2 had frontal hypoperfusion whereas no change from headache-free rCBF occurred in 7 patients. Statistical analysis of MCA velocities in 13 patients showed a significant decrease in the mean flow velocity compared with the headache-free values on the symptomatic side. Our findings suggest that the alteration of cerebral circulation during cluster attacks might be of secondary nature.
Collapse
Affiliation(s)
- J Afra
- Department of Neurology, Semmelweis Medical University, Budapest, Hungary
| | | | | | | | | |
Collapse
|